Ad5FGF-4 In Patients With Refractory Angina Due to Myocardial Ischemia
A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 160 participants.
Also called NCT02928094
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 160 participants
- Sponsor
- Angionetics Inc.
- Registry
-
NCT02928094
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Not reported
- Registry status
- Unknown status
Technical summary
Registry record NCT02928094. Randomized; triple masking; primary purpose treatment. Start 2023-01-01 (anticipated); primary completion 2024-03-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Ad5FGF-4 In Patients With Refractory Angina Due to Myocardial Ischemia
- Acronym
- AFFIRM
- Condition
- Angina, Stable
- Intervention (Biological)
- Ad5FGF-4
- Intervention (Biological)
- Placebo
- Lead sponsor
- Angionetics Inc.
- Collaborator
- Huapont Life Sciences
Record details
- Record id
cardio:ct-nct02928094- Content hash
59c4e88acb435ed6c7ef2a9819cfd40cb5b3f62b2a0a2b2feb6e1b2f272eb212